$MDXH Cashflow Statement | Understand Stock

$MDXH

$0.20 +$0.00 (1.18%) Close

$MDXH Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flow

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Operating loss
Depreciation
Amortization of intangible assets
Impairment
Share-based compensation
Provision for inventory obsolescence
Operating changes in fair value of contingent liabilities
Other non-cash transactions

Cash used in operations before working capital changes
Increase in inventories
Decrease / (increase) in receivables
Increase in payables
Net cash outflow from operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment
Acquisition and generation of intangible assets
Acquisition of Genomic Prostate Score Business
Earnout payment (GPS acquisition)
Cash from acquisition of Exosome Diagnostics
Interest received

Net cash outflow from investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of shares, net of transaction costs
Proceeds from the issuance of long-term debt
Proceeds from loan obligation
Repayment of loan obligation and debt extinguishment costs
Amendment fee related to OrbiMed Agreement
Earnout payment (GPS acquisition)
Amendment fee related to OrbiMed / GPS agreement
Payment of lease liability
Interests received
Payment of interest
Other financial expenses

Net cash inflow from financing activities
Net decrease (-) / increase (+) in cash and cash equivalents
Cash and cash equivalents at beginning of the financial year
Effect on exchange rate changes
Cash and cash equivalents at end of the financial year

Comments